Published
July 22, 2024
Updated
July 29, 2026
The $35 million Pfizer settlement resolved part of the Lipitor antitrust litigation; the claims period is closed and the administrator has not announced a distribution date.
Current Status
The court entered an order and judgment granting final approval of the Pfizer settlement. Claims closed November 29, 2024. The official site does not currently confirm that payments have been issued, and litigation involving Ranbaxy was not resolved by this settlement.StatusFinal approval granted; claims processing
Claim DeadlineNovember 29, 2024 (Passed)
BenefitVaries under the allocation plan
Proof RequiredPurchase information and supporting records were required
What Was This Case About?
End-payor plaintiffs alleged that Pfizer and Ranbaxy delayed generic competition for Lipitor and caused consumers and third-party payors to overpay. Pfizer denied the allegations and settled without admitting liability.Who Was Included?
The settlement covered qualifying consumers and third-party payors in specified states and territories who bought or reimbursed purchases of branded Lipitor or generic atorvastatin during the periods defined in the notice.How Were Awards Calculated?
Awards depend on qualifying purchases, claimant type, available documentation, and the court-approved allocation plan. New claims are not accepted.Official Information
Review notices and documents on the Lipitor Antitrust Settlement website.
Settlement Amount
$35 million
Case Title
In re Lipitor Antitrust Litigation
Case Number
3:12-cv-2389-ZNQ-JBD; MDL No. 2332
Court
U.S. District Court for the District of New Jersey
Current Milestone
Final approval granted; payment date not posted
Official Website
Lipitor Antitrust Settlement
For more class actions, recalls, and refunds, keep scrolling below.
